DDrare: Database of Drug Development for Rare Diseases

254. ポルフィリン症　［臨床試験数：34，薬物数：35（DrugBank：20），標的遺伝子数：17，標的パスウェイ数：30］

Searched query = "Porphyria", "Hereditary coproporphyria", "Erythropoietic protoporphyria", "X linked dominant protoporphyria"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = 5-probe cocktail; Afamelanotide; Aln-60519; Aln-as1; Cas # in d.3.9.1 for sodium salt. cas number 1639325-43-1 (parent acid); Cas# in d.3.9.1 for sodium salt. cas number 1639325-43-1 (parent acid); Chlorpromazine; Chlorpromazine hydrochloride; Colestipol; Colestyramine; Cuv1647; Cysteine; Cysteine hydrochloride; Deferasirox; Exjade; Givosiran; Givosiran (aln-as1); Harvoni; Heme arginate; Hemin; Hemin for injection; Hydroxychloroquine; Iron; Isoniazid; Luteinizing hormone; Luteinizing hormone-releasing factor; Mt-7117 high dose; Mt-7117 low dose; Oral iron; Panhematin; Porphobilinogen; Questran; Recombinant human porphobilinogen deaminase (porphozym); Sterile normal saline (0.9% nacl); Tin mesoporphyrin

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04056481	August 20, 2019	11 November 2019	Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria	Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)	Acute Hepatic Porphyria	Drug: Givosiran	Alnylam Pharmaceuticals		Not recruiting	12 Years	N/A	All		Phase 2	United States;France
2	NCT03520036	July 5, 2018	4 November 2019	Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria	Erythropoietic Protoporphyria (EPP)	Drug: MT-7117 low dose;Drug: MT-7117 high dose;Drug: Placebo	Mitsubishi Tanabe Pharma Development America, Inc.		Not recruiting	18 Years	75 Years	All	102	Phase 2	United States
3	NCT03505853	April 26, 2018	25 March 2019	A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)	A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE)	Acute Intermittent Porphyria (AIP);Acute Hepatic Porphyria (AHP);Porphyria, Acute Intermittent;Acute Porphyria	Drug: Givosiran;Drug: 5-probe cocktail	Alnylam Pharmaceuticals		Not recruiting	18 Years	65 Years	All	10	Phase 1	Sweden
4	EUCTR2017-002432-17-PL	12/04/2018	28 February 2019	Study on an Investigational Drug, Givosiran, for the Treatment of Acute Hepatic Porphyrias	ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias - ENVISION	Acute Hepatic Porphyrias (AHP) MedDRA version: 20.0 Level: PT Classification code 10036182 Term: Porphyria acute System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0 Level: LLT Classification code 10036184 Term: Porphyria hepatic System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Givosiran Product Code: ALN-AS1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ALN-60519 CAS Number: 1639325-44-2 Current Sponsor code: ALN-60519 Other descriptive name: CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 189- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Alnylam Pharmaceuticals, Inc.		Authorised			Female: yes Male: yes	74	Phase 3	United States;Taiwan;Finland;Spain;Italy;Switzerland;United Kingdom;France;Czech Republic;Mexico;Canada;Poland;Belgium;Brazil;Denmark;Australia;Bulgaria;Netherlands;Germany;Japan;Korea, Republic of;Sweden
5	EUCTR2016-002638-54-SE	20/12/2017	20 August 2018	Long-term Safety and Clinical Activity of ALN-AS1 in Patients with Acute Intermittent Porphyria (AIP), a rare metabolic disorder.	A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a Previous Clinical Study with ALN-AS1	Acute Intermittent Porphyria (AIP) MedDRA version: 20.0 Level: LLT Classification code 10000818 Term: Acute intermittent porphyria System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: Givosiran Product Code: ALN-AS1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ALN-60519 CAS Number: 1639325-44-2 Current Sponsor code: ALN-60519 Other descriptive name: CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 189-	Alnylam Pharmaceuticals, Inc.		Authorised			Female: yes Male: yes	24	Phase 1;Phase 2	United States;United Kingdom;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT03118674	August 10, 2017	15 July 2019	Harvoni Treatment Porphyria Cutanea Tarda	Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C	Porphyria Cutanea Tarda;Hepatitis C	Drug: Harvoni	Wake Forest University Health Sciences	Gilead Sciences;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH)	Recruiting	18 Years	N/A	All	49	Phase 2	United States
7	NCT02979249	December 2016	26 August 2019	Oral Iron for Erythropoietic Protoporphyrias	Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias	Erythropoietic Protoporphyria;EPP;X-linked Protoporphyria;XLP	Drug: Oral Iron	Icahn School of Medicine at Mount Sinai	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Not recruiting	18 Years	N/A	All	150	N/A	United States
8	NCT02943213	November 2016	16 December 2017	Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride	A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions	Anti-Psychotic;Management of Manifestations of Psychotic Disorders;Treatment of Schizophrenia;Control Nausea and Vomiting;Relief of Restlessness and Apprehension Before Surgery;Acute Intermittent Porphyria;Adjunct in the Treatment of Tetanus;Control Manifestations of the Manic Type of Mani-depressive Illness;Relief of Intractable Hiccups	Drug: Chlorpromazine Hydrochloride	Cycle Pharmaceuticals Ltd.	Parexel	Not recruiting	18 Years	65 Years	All	20	Phase 1	South Africa
9	NCT02949830	October 2016	11 November 2019	A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)	A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1	Acute Intermittent Porphyria	Drug: givosiran (ALN-AS1)	Alnylam Pharmaceuticals		Not recruiting	18 Years	N/A	All	17	Phase 1/Phase 2	United States;Sweden;United Kingdom
10	EUCTR2016-002638-54-GB	30/08/2016	25 June 2018	Long-term Safety and Clinical Activity of ALN-AS1 in Patients with Acute Intermittent Porphyria (AIP), a rare metabolic disorder.	A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a Previous Clinical Study with ALN-AS1	Acute Intermittent Porphyria (AIP) MedDRA version: 20.0 Level: LLT Classification code 10000818 Term: Acute intermittent porphyria System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Product Name: Givosiran Product Code: ALN-AS1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ALN-60519 CAS Number: 1639325-44-2 Current Sponsor code: ALN-60519 Other descriptive name: CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 189-	Alnylam Pharmaceuticals, Inc.		Authorised			Female: yes Male: yes	24	Phase 1;Phase 2	United States;United Kingdom;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT02922413	October 30, 2015	2 September 2019	Panhematin for Prevention of Acute Attacks of Porphyria	Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria	Acute Intermittent Porphyria;Hereditary Coproporphyria;Variegate Porphyria	Biological: Hemin for injection;Other: Placebo	The University of Texas Medical Branch, Galveston		Recruiting	18 Years	N/A	All	20	Phase 2	United States
12	NCT02452372	May 6, 2015	25 June 2018	A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)	A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)	Acute Intermittent Porphyria	Drug: givosiran (ALN-AS1);Drug: Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals		Not recruiting	18 Years	65 Years	All	40	Phase 1	United States;Sweden;United Kingdom
13	NCT02180412	April 28, 2014	26 August 2019	Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria	A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria	Acute Porphyrias	Biological: Panhematin;Other: Glucose	The University of Texas Medical Branch, Galveston		Not recruiting	18 Years	100 Years	All	40	Phase 2	United States
14	NCT02935400	April 28, 2014	26 August 2019	Acute Porphyria Biomarkers for Disease Activity	Acute Porphyrias: Biomarkers for Disease Activity and Response to Treatment	Acute Intermittent Porphyria;Hereditary Coproporphyria;Variegate Porphyria	Drug: Hemin	The University of Texas Medical Branch, Galveston		Not recruiting	18 Years	N/A	All	50	Phase 3	United States
15	NCT01605136	May 2012	30 September 2019	Phase III Confirmatory Study in Erythropoietic Protoporphyria	A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited		Not recruiting	18 Years	N/A	All	93	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT01550705	March 2012	19 October 2017	Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria	Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria	Erythropoietic Protoporphyria (EPP);X Linked Erythropoietic Protoporphyria	Drug: Isoniazid	University of Utah	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Icahn School of Medicine at Mount Sinai;University of Alabama at Birmingham;University of California, San Francisco;University of Texas	Not recruiting	18 Years	N/A	All	11	N/A	United States
17	NCT01422915	May 2011	16 December 2017	Sorbent Therapy of the Cutaneous Porphyrias	Sorbent Therapy of the Cutaneous Porphyrias	Erythropoietic Protoporphyria	Drug: Colestipol	Brigham and Women's Hospital		Not recruiting	22 Years	60 Years	All	4	Phase 2/Phase 3	United States
18	NCT01284946	January 2011	19 February 2015	Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda	A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload	Porphyria Cutanea Tarda	Drug: Exjade	Assistance Publique - Hôpitaux de Paris	Association pour l'Etude des Fonctions Digestives (AEFD)	Recruiting	18 Years	N/A	Both	45	Phase 2	France
19	NCT01097044	April 2010	19 February 2015	Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)	A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited		Not recruiting	18 Years	N/A	Both	77	Phase 2	United States
20	NCT00979745	September 2009	19 February 2015	Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited		Not recruiting	18 Years	70 Years	Both	70	Phase 3	Finland;France;Germany;Ireland;Netherlands;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	EUCTR2009-011018-51-NL	06/08/2009	3 April 2012	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP). - Multicentre Phase III EPP Study 2	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP). - Multicentre Phase III EPP Study 2	Erythropoietic Protoporphyria (EPP) MedDRA version: 9.1 Level: LLT Classification code 10015289 Term: Erythropoietic protoporphyria	Product Name: afamelanotide Product Code: CUV1647 Pharmaceutical Form: Implant Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Subcutaneous use	Clinuvel Pharmaceuticals Limited		Not Recruiting			Female: yes Male: yes	70	Phase 3	Finland;United Kingdom;Netherlands;Ireland
22	EUCTR2007-000636-13-GB	17/06/2008	12 June 2012	A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) - Multicentre Phase III EPP Study	A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) - Multicentre Phase III EPP Study	Erythropoietic Protoporphyria (EPP) MedDRA version: 9.1 Level: LLT Classification code 10015289 Term: Erythropoietic protoporphyria	Product Name: CUV1647 Product Code: CUV1647 Pharmaceutical Form: Implant Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Subcutaneous use	Clinuvel Pharmaceuticals Limited		Authorised			Female: yes Male: yes	80	Phase 3	Germany;United Kingdom;Netherlands;France;Italy;Sweden
23	NCT00599326	January 2008	19 October 2017	Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda	Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda	Porphyria Cutanea Tarda	Drug: Deferasirox	University of Texas Southwestern Medical Center	Novartis Pharmaceuticals	Not recruiting	18 Years	N/A	All	10	Phase 3	United States
24	EUCTR2007-002863-28-GB	26/09/2007	26 November 2018	Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001	Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001	Erythropoietic protoporphyria (EPP) MedDRA version: 9.1 Level: LLT Classification code 10015289 Term: Erythropoietic protoporphyria	Trade Name: Questran Product Name: Questran Pharmaceutical Form: Powder for oral suspension INN or Proposed INN: COLESTYRAMINE CAS Number: 11041126 Concentration unit: g gram(s) Concentration type: equal Concentration number: 4-	Guy's & St Thomas' NHS Foundation Trust		Not Recruiting			Female: yes Male: yes	21	Phase 4	United Kingdom
25	NCT04053270	May 2007	22 October 2019	Multicentre Phase III Erythropoietic Protoporphyria Study	A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP)	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited		Not recruiting	18 Years	70 Years	All	100	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	NCT01573754	March 21, 2006	26 August 2019	Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda	A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435	Porphyria Cutanea Tarda	Drug: Hydroxychloroquine;Procedure: Phlebotomy	The University of Texas Medical Branch, Galveston		Recruiting	18 Years	100 Years	All	100	Phase 2	United States
27	NCT00418795	June 11, 2003	11 June 2018	Porphozym in the Treatment of Acute Attacks in AIP	A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP	Acute Intermittent Porphyria	Drug: recombinant human porphobilinogen deaminase (Porphozym)	Zymenex A/S		Not recruiting	18 Years	N/A	All	36	Phase 2/Phase 3	United States
28	NCT00004397	January 1998	19 February 2015	Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria		Porphyria	Drug: heme arginate;Drug: tin mesoporphyrin	National Center for Research Resources (NCRR)	University of Texas	Not recruiting	18 Years	N/A	Both	20	Phase 1
29	NCT00004398	January 1998	19 February 2015	Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria		Porphyria	Drug: heme arginate;Drug: tin mesoporphyrin	National Center for Research Resources (NCRR)	University of Texas	Not recruiting	18 Years	N/A	Both	24	Phase 1
30	NCT00004396	September 1997	19 February 2015	Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias		Porphyria	Drug: heme arginate;Drug: tin mesoporphyrin	National Center for Research Resources (NCRR)	University of Texas	Not recruiting	18 Years	N/A	Both	32	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT00004831	October 1996	7 April 2015	Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria		Erythropoietic Protoporphyria	Drug: cysteine hydrochloride	FDA Office of Orphan Products Development	St. Luke's-Roosevelt Hospital Center	Not recruiting	18 Years	65 Years	Both	20	N/A
32	NCT00004940	May 1996	7 April 2015	Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria		Erythropoietic Protoporphyria	Drug: cysteine hydrochloride	Brigham and Women's Hospital		Not recruiting	18 Years	65 Years	Both	50	Phase 3
33	NCT00004789	July 1993	19 February 2015	Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria		Porphyria	Drug: heme arginate;Drug: tin mesoporphyrin	National Center for Research Resources (NCRR)	University of Texas	Not recruiting	18 Years	N/A	Both	59	Phase 1/Phase 2
34	NCT00004330	March 1987	19 February 2015	Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks		Porphyria	Drug: luteinizing hormone-releasing factor	National Center for Research Resources (NCRR)	University of Texas	Not recruiting	18 Years	55 Years	Female		N/A	United States

先頭へ